Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2018Journal of Hematology & OncologyOpen Access

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

FRFederico RossariVita-Salute San Raffaele UniversityFMFilippo MinutoloUniversity of PisaEOEnrico OrciuoloAzienda Ospedaliera Universitaria Pisana

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rossari et al. (2018) studied this question.

synapsesocial.com/papers/6a73500a396a0d6d0bf12d9ahttps://doi.org/10.1186/s13045-018-0624-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy2016 · 197 citations
  2. 2The Ins and Outs of Bcr-Abl Inhibition2012 · 123 citations
  3. 3Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia2016 · 53 citations